A joint venture between US-based Emergent Biosolutions, and Singapore's Temasek Life Sciences Lab, Epic Bio will build a comprehensive range of capabilities to support the company's R&D of the H5N1 influenza vaccine and monoclonal antibody. These capabilities include vaccinology, immunology, epidemiology, assay development, quality assurance, regulatory affairs, R&D project management, as well as market and technology assessment.